This analysis suggested that teriflunomide, interferons, GLAT and S1P modulators were associated with higher odds of PsO worsening, while CD20 therapies and natalizumab showed a trend toward increased risk without clear significance.
← all excerpts
Treatment approaches to patients with multiple sclerosis and coexisting psoriasis - A longitudinal multicenter observational cohort study.
1
—
—